istock-643956998_jirsak
jirsak / iStockphoto.com
5 December 2018Americas

Allele Biotech partners with Scientist.com to develop nanoantibodies

US-based  Allele Biotechnology & Pharmaceuticals, a preclinical-stage biopharmaceutical company, has teamed up with a scientific e-commerce marketplace network in efforts to develop nanoantibodies for therapeutic applications.

Scientist.com, which was launched in 2008, is a network of public and private online marketplaces that connect buyers (such as researchers) with sellers of research services.

Although the site is US-based, research suppliers in more than 100 countries now use Scientist.com, and the platform claims to offer “innovation on demand” by hosting more than 3,500 research technologies and more than 17,500 global suppliers.

As part of the partnership,  announced on Monday, December 3, Scientist.com’s new Genius Consulting Network will be used to assist Allele in applying its proprietary nanoantibody technology to multiple therapeutic areas.

“Allele’s nanoantibodies are recombinant, fully humanised, camelid single-domain heavy-chain only antibodies that can be linked together to produce multivalent new molecular entities,” Allele’s release said.

“With their unique structure, small size, and ability to bind multiple targets with one construct, nanoantibodies are ideal for generating novel biologics,” it added.

The companies hope that the combination of their expertise will result in the creation of innovative biologics programmes, by connecting Allele’s nanoantibodies with experts in preclinical and clinical research through the Genius Consulting Network.

Jiwu Wang, CEO of Allele, said: “Scientist.com makes it easy for us to connect with industry-leading experts in drug discovery and development. We use the marketplace to find the experts and services we need for our internal research and development programmes.”

Scientist.com’s network provides access to experts around the world with specialisms covering investigational new drug programmes, translational research, new drug applications, and other areas.

Kevin Lustig, CEO and founder of Scientist.com, said that Allele’s nanoantibody technologies are novel and cutting-edge, with “considerable therapeutic potential”.

“This partnership enables Allele to focus on exploring therapeutic applications of its proprietary nanoantibody candidates,” he said.

Allele is not the only nano-related technology company generating attention.

Earlier this year, biopharmaceutical company Sanofi  revealed its plans to purchase biotech firm Ablynx, which uses nanobody technology to develop therapeutic treatments for haematology, inflammation, and respiratory disease, for approximately €3.9 billion ($4.8 billion).

Did you enjoy reading this story?  Sign up to our free newsletters and get stories like this sent straight to your inbox.


More on this story

Big Pharma
29 January 2018   Biopharmaceutical company Sanofi has revealed plans to acquire biotech firm Ablynx for approximately €3.9 billion ($4.8 billion).
Biotechnology
6 January 2022   Biotech Allele has dropped its lawsuit accusing Pfizer and BioNTech of infringing technology covering a fluorescent protein used in COVID-19 vaccines.

More on this story

Big Pharma
29 January 2018   Biopharmaceutical company Sanofi has revealed plans to acquire biotech firm Ablynx for approximately €3.9 billion ($4.8 billion).
Biotechnology
6 January 2022   Biotech Allele has dropped its lawsuit accusing Pfizer and BioNTech of infringing technology covering a fluorescent protein used in COVID-19 vaccines.